Huahaipharm

BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious

BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.

Bio-based Materials Manufacturer Mojia Bio Nets USD 80 Mn in Series B Round

For synthetic biology companies, the bottlenecks are controlling the cost and achieving industrialization.

RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round

Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.

Noah Hospital Logistics Robot Received over Ten Million CNY in Series B+ Round

Noah Hospital Logistics Robot recently received over ten million CNY in Series B+ round, with most of the funds going toward product development and marketing.

AI-driven pharmaceutics Company Helixon Raise CNY 500 Mn in Series A Round

As one of the key players in computational biology, Helixon received recognition from the capital market for its innovation in machine learning algorithms and data acquisition technologies which reconstruct the drug development process and improve the efficiency of new drug development.